Compare BUD & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUD | PFE |
|---|---|---|
| Founded | 1366 | 1849 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4B | 145.4B |
| IPO Year | N/A | N/A |
| Metric | BUD | PFE |
|---|---|---|
| Price | $64.79 | $25.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 10 |
| Target Price | ★ $71.50 | $27.40 |
| AVG Volume (30 Days) | 2.1M | ★ 52.7M |
| Earning Date | 10-30-2025 | 02-03-2026 |
| Dividend Yield | 1.50% | ★ 6.83% |
| EPS Growth | N/A | ★ 131.89 |
| EPS | ★ 3.00 | 1.73 |
| Revenue | $58,605,000,000.00 | ★ $62,785,000,000.00 |
| Revenue This Year | $0.69 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $20.82 | ★ $14.64 |
| Revenue Growth | N/A | ★ 3.89 |
| 52 Week Low | $45.94 | $20.92 |
| 52 Week High | $72.13 | $27.69 |
| Indicator | BUD | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 47.74 |
| Support Level | $64.26 | $24.92 |
| Resistance Level | $65.57 | $26.65 |
| Average True Range (ATR) | 0.87 | 0.58 |
| MACD | 0.34 | -0.09 |
| Stochastic Oscillator | 83.95 | 17.63 |
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.